Earnings call transcript: Bausch Health Q2 2025 sees revenue growth, stock dips

Bausch Health (BHC) reported robust Q2 2025 results, with EPS of $0.40 significantly exceeding forecasts by 900% and revenue of $2.53 billion, up 5% year-over-year, driven by strong performance in segments like Solta Medical. Despite this operational strength and reaffirmed full-year 2025 guidance, the stock fell 13.64% in after-hours trading, reflecting investor concerns potentially tied to future growth prospects, ongoing litigation, or the impact of the XIFAXAN IRA. The company continues to prioritize deleveraging, having completed a $7.9 billion debt refinancing, and announced the proposed acquisition of Direct Corporation to expand its hepatology portfolio.

Analysis

Bausch Health Companies Inc. (BHC) presented a paradoxical Q2 2025, reporting fundamentally strong operational results that were met with a significant negative market reaction. The company delivered a ninth consecutive quarter of revenue and adjusted EBITDA growth (excluding Bausch + Lomb), with total revenue rising 5% year-over-year to $2.53 billion and an exceptional 900% earnings per share surprise, posting $0.40 versus a $0.04 forecast. Growth was robust in key segments, including a 25% revenue increase in Solta Medical and a 12% rise in the Salix business, driven by XIFAXAN's continued momentum. Management reaffirmed full-year 2025 guidance, projecting 4% revenue growth at the midpoint, and highlighted strategic progress with a $7.9 billion debt refinancing and the proposed acquisition of Direct Corporation to expand its hepatology pipeline. Despite these positive metrics and an InvestingPro assessment suggesting undervaluation with a 40% free cash flow yield, the stock plummeted 13.64% in after-hours trading. This sharp decline likely reflects investor apprehension over forward-looking risks, chiefly the uncertain pricing impact on XIFAXAN from ongoing IRA negotiations, persistent litigation, and the new risk associated with acquiring a pipeline asset that previously missed a primary endpoint.

Key Decisions for Investors

• Investors should weigh the company's strong operational performance and valuation metrics against significant forward-looking risks, particularly the pending XIFAXAN IRA pricing outcome which appears to be the primary driver of the stock's negative reaction.
• Given that capital allocation is now prioritized for deleveraging and the Direct Corporation acquisition over share buybacks, investors should re-evaluate their expectations for near-term capital returns and focus on the long-term potential of these strategic moves.
• It is critical to monitor catalysts that could resolve the current uncertainty, including the conclusion of IRA pricing negotiations in late 2025 and clinical updates on the newly acquired larsucostol asset.
• The sharp stock decline post-earnings may present an opportunity for value-oriented investors, but this position requires a high tolerance for volatility driven by regulatory and litigation-related headlines.